| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2009 , Vol 51 , Num 1
EFFECT OF SILYMARIN SUPPLEMENT ON THE PHARMACOKINETICS OF ORNIDAZOLE IN HEALTHY VOLUNTEERS
Centre for Biopharmaceutics and Pharmacokinetics, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh, India
Viewed :
20207
-
Downloaded :
6275
The objective of investigation was to study the influence of silymarin pretreatment on the pharmacokinetics of ornidazole in healthy human volunteers. A single oral dose of ornidazole (500 mg) tablet was administered to nine volunteers, either alone or after 9 days pretreatment with a daily dose of silymarin (140 mg) capsule after an overnight fasting. Blood samples were collected from antecubital vein for 48 h, and the serum concentration of ornidazole was determined using HPLC. Silymarin treatment resulted in the significant increase in AUC (0-), Cmax, and t1/2 by 30.25 %, 16.25 %, and 7.697 % respectively. Silymarin, a mixture of flavonolignans may alter the pharmacokinetics of ornidazole, probably by inhibiting the cytochrome P450 enzymes and p-glycoprotein.
Keywords :
SILYMARIN, ORNIDAZOLE, HEALTHY HUMAN VOLUNTEERS, PHARMACOKINETICS